Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Jun. 2026,
PT Jayamas Medica Industri Tbk paidRp0 Mil more to buy back shares than it received from issuing new shares.
It spentRp833 Mil paying down its debt.
It paidRp0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedRp0 Mil from paying cash dividends to shareholders.
It receivedRp1,690 Mil on other financial activities.
In all, PT Jayamas Medica Industri TbkearnedRp857 Mil on financial activities for the
three
months ended in Jun. 2026.
PT Jayamas Medica Industri Tbk (ISX:OMED) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
PT Jayamas Medica Industri Tbk's issuance of stock for the
three
months ended in Jun. 2026 was Rp0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
PT Jayamas Medica Industri Tbk's repurchase of stock for the
three
months ended in Jun. 2026 was Rp0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
PT Jayamas Medica Industri Tbk's net issuance of debt for the
three
months ended in Jun. 2026 was Rp-833 Mil.
PT Jayamas Medica Industri Tbk spentRp833 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
PT Jayamas Medica Industri Tbk's net issuance of preferred for the
three
months ended in Jun. 2026 was Rp0 Mil.
PT Jayamas Medica Industri Tbk paidRp0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
PT Jayamas Medica Industri Tbk's cash flow for dividends for the
three
months ended in Jun. 2026 was Rp0 Mil.
PT Jayamas Medica Industri Tbk receivedRp0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
PT Jayamas Medica Industri Tbk's other financing for the
three
months ended in Jun. 2026 was Rp1,690 Mil.
PT Jayamas Medica Industri Tbk receivedRp1,690 Mil on other financial activities.
PT Jayamas Medica Industri Tbk Cash Flow from Financing Related Terms
PT Jayamas Medica Industri Tbk Cash Flow from Financing Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Jayamas Medica Industri Tbk Cash Flow from Financing Chart
PT Jayamas Medica Industri Tbk Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp113,251 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of Rp113,251 Mil mean?
PT Jayamas Medica Industri Tbk (ISX:OMED) has a Cash Flow from Financing of Rp113,251 Mil as of Jun. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for PT Jayamas Medica Industri Tbk and its competitors.
Is PT Jayamas Medica Industri Tbk's Cash Flow from Financing too high?
PT Jayamas Medica Industri Tbk's current Cash Flow from Financing is Rp113,251 Mil. Overall, PT Jayamas Medica Industri Tbk has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PT Jayamas Medica Industri Tbk's Cash Flow from Financing compare to ISRG and BDX?
PT Jayamas Medica Industri Tbk's Cash Flow from Financing of Rp113,251 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Medical Devices & Instruments company?
A good Cash Flow from Financing depends on the Medical Devices & Instruments industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for PT Jayamas Medica Industri Tbk and its competitors. PT Jayamas Medica Industri Tbk's current Cash Flow from Financing is Rp113,251 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Jayamas Medica Industri Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk (ISX:OMED) is currently considered Fairly Valued. The stock's GF Value™ is Rp239.79, compared to a current price of Rp242.00 — trading 0.9% above its estimated fair value. The current Cash Flow from Financing is Rp113,251 Mil. PT Jayamas Medica Industri Tbk's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For PT Jayamas Medica Industri Tbk (ISX:OMED), the current Cash Flow from Financing is Rp113,251 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Jayamas Medica Industri Tbk (ISX:OMED) Overvalued in 2026?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk stock appears to be overvalued.
The current stock price of Rp242.00 is trading 0.9% above its estimated GF Value™ of Rp239.79.
GuruFocus considers PT Jayamas Medica Industri Tbk to be Fairly Valued.
Key valuation signals for ISX:OMED:
Cash Flow from Financing: Rp113,251 Mil
GF Value™: Rp239.79 vs. price of Rp242.00 (0.9% above fair value)
No single metric tells the full story. See the ISX:OMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Jayamas Medica Industri Tbk is engaged in the business of manufacturing, wholesale and retail trade of medical devices. Its offerings include Disposable and Expendable Medical Supplies, Wound Care, Diagnostics and Equipment, Antiseptics and Dialysis, Biotechnology and Laboratory, Ambulatory and Rehabilitation Care The company has three segments: i) Manufacturing: This division is involved in the manufacturing of medical supplies and equipment, ii) Distribution: This division is involved with the large scale distribution of medical supplies and equipment at strategic locations, iii) Retail: This division is involved with the retail of medical supplies and equipment through Medicom stores and online platforms. The majority of the company's revenue is derived from the Distribution segment.
89GF Score
Get the complete analysis for ISX:OMED
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:OMED has been successfully added to your 
